Genelux (GNLX)

Profile

Full Name

Genelux Corporation

Ticker Symbol

GNLX

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

January 26, 2023

Indexes

Not included

Website

http://www.genelux.com

Employees

24

Key Details

Price

$2.60(+1.25%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$8000.00(-95.29% YoY)

Annual EPS

-$0.95(+18.10% YoY)

PE ratio

-

Next earnings date

May 9, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$2.60
GNLX price is $2.60

30-Day Relative Volume

0.87
GNLX 30-day relative volume is 0.87

Price Performance

Price Today change

+1.25%
GNLX price is up +1.25% today

Price YTD change

+10.26%
GNLX price is up +10.26% since January 1st

Price 1-year change

-28.02%
GNLX price is down -28.02% year-on-year

Price 3-year change

-
GNLX price 3-year change is unknown

Price Range

Price All-time high

$40.98
GNLX price is currently -93.65% below its historical high of $40.98

Price 3-year low

$1.60
GNLX price is currently +62.63% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$97.85M
GNLX market capitalization is $97.85 million

Market cap 3-year change

-
GNLX market capitalization 3-year change is unknown

Market cap All-time high

$971.48M
GNLX market capitalization is currently -89.93% below its historical high of $971.48 million

Market cap sector rank

48.6%
GNLX market capitalization is higher than 48.6% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+39.29%
GNLX shares outstanding is up +39.29% year-on-year

Shares Outstanding 3-Year Change

-
GNLX shares outstanding 3-year change is unknown

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.16
GNLX beta is 1.16

200-day SMA

$2.83
GNLX price is currently -7.90% below its 200-day simple moving average

50-day SMA

$3.72
GNLX price is currently -30.05% below its 50-day simple moving average

RSI

40.50
GNLX 14-day relative strength index is 40.50

Volume

0.87
GNLX 30-day relative volume is 0.87

ATR

$0.30
GNLX average true range is $0.30

10-day Historical Volatility

92.11%
GNLX 10-day historical volatility is 92.11%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$8000.00
GNLX annual revenue is $8000.00

Revenue Analysts estimate

-
GNLX annual revenue consensus analysts' forecast is unknown

Revenue 1-year change

-95.29%
GNLX annual revenue is down -95.29% year-on-year

Revenue Sector rank

1.9%
GNLX annual revenue is higher than 1.9% of companies in Healthcare sector

EPS

EPS

-$0.95
GNLX annual earnings per share is -$0.95

EPS Analysts estimate

-$1.02
GNLX annual earnings per share is currently -6.63% lower than the consensus analysts' forecast

EPS 1-year change

+18.1%
GNLX annual earnings per share is up +18.1% year-on-year

EPS Sector rank

57.69%
GNLX annual earnings per share is higher than 57.69% of companies in Healthcare sector

Profit

Gross profit

-
GNLX annual gross profit value is unknown

Gross margin

-
GNLX annual gross profit margin value is unknown

Operating profit

-$31.70M
GNLX annual operating income is -$31.70 million

Operating margin

-396.20K%
GNLX annual operating profit margin is -396.20 thousand%

Net income

-$29.87M
GNLX annual net profit is -$29.87 million

Net margin

-373.36K%
GNLX annual net profit margin is -373.36 thousand%

Expenses

Total expenses

$31.70M
GNLX annual total expenses is $31.70 million

Operating expenses

$31.70M
GNLX annual total operating expenses is $31.70 million

Cost of goods sold

-
GNLX annual cost of goods sold value is unknown

Selling, general & administrative expenses

$12.71M
GNLX annual SGA is $12.71 million

Depreciation and amortization

$903.00K
GNLX annual depreciation & amortization is $903.00 thousand

Interest expense

$0.00
GNLX annual interest expense is $0.00

Income tax

-
GNLX annual income tax value is unknown

EBIT & EBITDA

EBIT

-$29.87M
GNLX annual earnings before interest & taxes is -$29.87 million

EBITDA

-$28.97M
GNLX annual EBITDA is -$28.97 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$34.72M
GNLX annual total assets is $34.72 million

Non current assets

$3.17M
GNLX annual long term assets is $3.17 million

Current assets

$31.55M
GNLX annual total current assets is $31.55 million

Cash and cash equivalents

$8.56M
GNLX annual cash & cash equivalents is $8.56 million

Accounts receivable

-
GNLX annual accounts receivable value is unknown

Inventory

-
GNLX annual inventory value is unknown

Liabilities

Total liabilities

$8.44M
GNLX annual total liabilities is $8.44 million

Long term liabilities

$1.54M
GNLX annual total long term liabilities is $1.54 million

Current liabilities

$6.90M
GNLX annual total current liabilities is $6.90 million

Accounts payable

$5.57M
GNLX annual accounts payable is $5.57 million

Debt

Total debt

$1.87M
GNLX annual total debt is $1.87 million

Total debt 1-year change

-25.84%
GNLX annual total debt is down -25.84% year-on-year

Long term debt

$1.54M
GNLX annual long term debt is $1.54 million

Short term debt

$329.00K
GNLX annual short term debt is $329.00 thousand

Equity & Capital

Shareholders equity

$26.27M
GNLX annual stockholders equity is $26.27 million

Book value

$26.27M
GNLX annual book value is $26.27 million

Retained earnings

-$251.39M
GNLX annual retained earnings is -$251.39 million

Working capital

$24.64M
GNLX annual working capital is $24.64 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$21.23M
GNLX annual cash flow from operations is -$21.23 million

Cash from operations 1-year change

-4.7%
GNLX annual cash flow from operations is down -4.7% year-on-year

Cash from investing

-$8.13M
GNLX annual cash flow from investing activities is -$8.13 million

Cash from investing 1-year change

+44.78%
GNLX annual cash flow from investing activities is up +44.78% year-on-year

Cash from financing

$28.51M
GNLX annual cash flow from financing activities is $28.51 million

Cash from financing 1-year change

-35.24%
GNLX annual cash flow from financing activities is down -35.24% year-on-year

CAPEX

CAPEX

$381.00K
GNLX annual capital expenditures is $381.00 thousand

CAPEX 1-year change

-62.83%
GNLX annual capital expenditures is down -62.83% year-on-year

Free Cash Flow

Free cash flow

-$21.61M
GNLX annual free cash flow is -$21.61 million

Free cash flow 1-year change

-1.45%
GNLX annual free cash flow is down -1.45% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
GNLX annual gross profit margin value is unknown

Operating margin

-396.20K%
GNLX annual operating profit margin is -396.20 thousand%

Net margin

-373.36K%
GNLX annual net profit margin is -373.36 thousand%

ROA & ROE

ROA

-95.41%
GNLX annual return on assets is -95.41%

ROE

-130.58%
GNLX annual return on equity is -130.58%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
GNLX price to earnings ratio value is unknown

PE ratio Sector rank

-
GNLX price to earnings ratio is unknown

PB Ratio

PB ratio

3.72
GNLX price to book ratio is 3.72

PB ratio Sector rank

77.59%
GNLX price to book ratio is higher than 77.59% of companies in Healthcare sector

PS Ratio

PS ratio

-
GNLX price to sales ratio value is unknown

PS ratio Sector rank

-
GNLX price to sales ratio is unknown

Enterprise value

Enterprise value

$91.15M
GNLX enterprise value is $91.15 million

Enterprise value Sector rank

49.22%
GNLX enterprise value is higher than 49.22% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-3.15
GNLX EV/EBITDA is -3.15

EV/EBITDA Sector rank

25.3%
GNLX EV/EBITDA is higher than 25.3% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

4.57
GNLX annual current ratio is 4.57

Quick ratio

-
GNLX annual quick ratio value is unknown

Leverage

Debt to equity

0.00
GNLX annual debt to equity ratio is 0.00

Interest coverage ratio

-
GNLX annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
GNLX piotroski f-score value is unknown

Altman Z-Score

-5.17
GNLX altman z-score is -5.17

Analyst ratings

Recent major analysts updates

Mar 31, 25 HC Wainwright & Co.
Buy
Mar 25, 25 HC Wainwright & Co.
Buy
Nov 15, 24 HC Wainwright & Co.
Buy
Oct 29, 24 Guggenheim
Buy
Aug 27, 24 Roth MKM
Buy
Aug 15, 24 HC Wainwright & Co.
Buy
Jun 3, 24 Benchmark
Speculative Buy
May 31, 24 Benchmark
Speculative Buy
May 13, 24 HC Wainwright & Co.
Buy
Apr 3, 24 Benchmark
Speculative Buy

Institutional Ownership

Similar stocks

ALEC logo
Alector (ALEC)
LCTX logo
Lineage Cell Therapeutics (LCTX)
Invizyne Technologies (IZTC)
RPID logo
Rapid Micro Biosystems (RPID)
LUCD logo
Lucid Diagnostics (LUCD)
TIL logo
Instil Bio (TIL)
SNTI logo
Senti Biosciences (SNTI)
AIRS logo
AirSculpt Technologies (AIRS)
eXoZymes (EXOZ)
  • What is the ticker symbol for Genelux?
  • Does Genelux pay dividends?
  • What sector is Genelux in?
  • What industry is Genelux in?
  • What country is Genelux based in?
  • When did Genelux go public?
  • Is Genelux in the S&P 500?
  • Is Genelux in the NASDAQ 100?
  • Is Genelux in the Dow Jones?
  • When was Genelux's last earnings report?
  • When does Genelux report earnings?
  • Should I buy Genelux stock now?

What is the ticker symbol for Genelux?

The ticker symbol for Genelux is NASDAQ:GNLX

Does Genelux pay dividends?

No, Genelux does not pay dividends

What sector is Genelux in?

Genelux is in the Healthcare sector

What industry is Genelux in?

Genelux is in the Biotechnology industry

What country is Genelux based in?

Genelux is headquartered in United States

When did Genelux go public?

Genelux's initial public offering (IPO) was on January 26, 2023

Is Genelux in the S&P 500?

No, Genelux is not included in the S&P 500 index

Is Genelux in the NASDAQ 100?

No, Genelux is not included in the NASDAQ 100 index

Is Genelux in the Dow Jones?

No, Genelux is not included in the Dow Jones index

When was Genelux's last earnings report?

Genelux's most recent earnings report was on Mar 28, 2025

When does Genelux report earnings?

The next expected earnings date for Genelux is May 9, 2025

Should I buy Genelux stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page